New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTDYAX, BCRXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Check below for free stories on DYAX;BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
08:05 EDTDYAXDyax announces publication of DX-2930 scientific data
Dyax announced the online publication of scientific data for DX-2930 in two peer-reviewed journals. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. The first paper titled “A Phase 1 Study Investigating DX-2930 in Healthy Subjects” by Chyung et al. was published online in the Annals of Allergy, Asthma and Immunology. These data indicate that DX-2930 has a long half-life in humans and thus the potential for prophylactic inhibition of pKal activity for the therapeutic treatment of HAE. DX-2930 is now being evaluated in a Phase 1b study in patients with HAE. The second paper titled “Inhibition of Plasma Kallikrein by a Highly Specific, Active Site Blocking Antibody” by Kenniston et al. was published online in The Journal of Biological Chemistry. The paper describes the discovery and preclinical evaluation of DX-2930 as a long-acting inhibitor of pKal proteolytic activity. This paper is expected to appear in the September 2014 print issue of the journal. The company said, "These data, combined with data that will be obtained from the ongoing Phase 1b study, will inform and guide the future clinical development of DX-2930.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use